Log In
BCIQ
Print this Print this
 

TAC-201

  Manage Alerts
Collapse Summary General Information
Company Meiji Seika Pharma Co. Ltd.
DescriptionRecombinant T cell epitope consensus peptide for immunotherapy of Japanese cedar pollinosis
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsTreat pollen allergy to Japanese cedar
Regulatory Designation
PartnerTaiho Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today